Drug Profile


Alternative Names: ACZ-885; Anti-IL-1 beta monoclonal antibody; Anti-interleukin-1 beta monoclonal antibody; Antibody A; Ilaris

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; Triemli hospital; University Hospital Tubingen; University Hospital Zurich
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Juvenile rheumatoid arthritis; Inflammation; Familial Mediterranean fever; Familial autosomal dominant periodic fever
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adult-onset Still's disease; Cryopyrin-associated periodic syndromes; Familial autosomal dominant periodic fever; Familial Mediterranean fever; Gouty arthritis; Juvenile rheumatoid arthritis; Peroxisomal disorders
  • Phase III Behcet's syndrome; Cardiovascular disorders
  • Phase II Abdominal aortic aneurysm; Atherosclerosis; Osteoarthritis; Peripheral arterial occlusive disorders; Pulmonary sarcoidosis
  • Phase I Diabetic retinopathy
  • No development reported Chronic obstructive pulmonary disease
  • Discontinued Asthma; Polymyalgia rheumatica; Rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 04 Apr 2017 Novartis intends to submit NDA to the US FDA for Cardiovascular disorders (Prevention) in 2017
  • 16 Feb 2017 Novartis withdraws a phase II trial in Mucocutaneous Lymph Node Syndrome (In neonates, In infants, In children) prior to enrolment in Belgium, Germany, Italy (NCT02980263) (EudraCT2015-003763-11)
  • 16 Dec 2016 The Committee for Medicinal Products for Human Use recommends approval of canakinumab for the treatment of Familial autosomal dominant periodic fever, Peroxisomal disorders and Familial Mediterranean Fever in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top